Alzheimer's disease – Related resources
- Selegiline may not have clinically significant effects on cognitive performance, mood and behaviour in Alzheimer's disease [Evidence Level: C].
- There is no evidence that clioquinol (PBT1) would provide any clinical benefit for patients with Alzheimer's disease [Evidence Level: D].
- Atypical antipsychotics are beneficial in the treatment of aggression, agitation and psychosis in people with Alzheimer's disease, but the risks of adverse events may outweigh the benefits, particularly with long term treatment [Evidence Level: A]
- Statins are probably not effective for the treatment of Alzheimer's disease [Evidence Level: B].
- Propentofylline may benefit cognition, global function and activities of daily living of people with Alzheimer's disease and/or vascular dementia [Evidence Level: C].
Other evidence summaries
- There is insufficient evidence on improved patient outcomes on brain single-photon enhanced computed tomography (SPECT) in differentiating Alzheimer's disease (AD) from other dementias [Evidence Level: D].
- High-dose B vitamin supplements do not slow cognitive decline in individuals with mild to moderate Alzheimer’s disease [Evidence Level: A].
- Early-onset autosomal dominant Alzheimer disease. Orphanet ORPHA1020 http://www.orpha.net/consor/cgi-bin/Disease_Search.php...
- Mayeux R. Clinical practice. Early Alzheimer's disease. N Engl J Med 2010 Jun 10;362(23):2194-201. [PMID:20558370]
- Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008 Mar 4;148(5):379-97 [PMID:18316756]
Copyright © 2017 Duodecim Medical Publications Limited.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.